Nov 13, 2023 5:17pm EST SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Oct 24, 2023 8:00am EDT SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)
Oct 16, 2023 8:00am EDT SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece
Sep 27, 2023 8:31pm EDT SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance
Aug 14, 2023 4:30pm EDT SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Jul 20, 2023 9:58am EDT SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China
Jun 21, 2023 7:00am EDT SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK
May 12, 2023 8:00am EDT SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)
